Under construction – not a live service
Sign in
Taking people in ChinaNo phase

CAIX-targeted PET/CT scans for detecting solid tumors in adults

Tests a scan using 68Ga-CAIX to find solid tumors in adults.

Plain-language title generated from the registry record
Registry title: CAIX-targeted PET/CT in Solid Tumors

Key facts

Where
Wuhan, ChinaSee the site

Where in China

  • Zhongnan Hospital of Wuhan UniversityWuhan, ChinaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Zhongnan Hospital
Trial code
NCT07833085
Record updated
13 October 2026
Original description
Tumor hypoxic microenvironment plays an important role in the initiation and progression of solid tumors, as well as tumor invasion, metastasis, and treatment resistance. Carbonic anhydrase IX (CAIX), as a crucial downstream molecule regulated by hypoxia-inducible factor-1 (HIF-1), is highly expressed in various solid tumors and is closely associated with tumor invasiveness, treatment response, and prognosis; thus, it represents an ideal target for tumor diagnosis and therapy. This study aims to explore the diagnostic value of CAIX-targeted PET/CT imaging in various solid tumors, as well as the correlation between tumor uptake and tissue CAIX expression.Read full original descriptionShow less

Carbonic Anhydrase IX-targeted PET/CT Imaging for Detecting Solid Tumors

Tumor hypoxic microenvironment plays an important role in the initiation and progression of solid tumors, as well as tumor invasion, metastasis, and treatment resistance. Carbonic anhydrase IX (CAIX), as a crucial downstream molecule regulated by hypoxia-inducible factor-1 (HIF-1), is highly expressed in various solid tumors and is closely associated with tumor invasiveness, treatment response, and prognosis; thus, it represents an ideal target for tumor diagnosis and therapy. This study aims to explore the diagnostic value of CAIX-targeted PET/CT imaging in various solid tumors, as well as the correlation between tumor uptake and tissue CAIX expression.

Inclusion: Participants with suspected malignant solid tumors or patients with newly diagnosed or recurrent/metastatic malignant solid tumors confirmed by histopathology; Age of 18 years and above, both male and female are eligible; The ECOG PS score for physical condition in the Eastern Cancer Collaboration Group is 0-1 points; Research participants voluntarily sign informed consent forms or have their parents/children/legal guardians sign informed consent forms, and are able to complete the trial according to the requirements of the research protocol.

Exclusion: Participants with severe liver and kidney dysfunction and cardiac dysfunction; Participants with severe obesity, claustrophobia, or other reasons who are unable to undergo PET scans; Pregnant or lactating women; Other situations that researchers believe should be excluded and documented.

ClinicalTrials.gov NCT07833085